SpliSense Ltd., is a growing and exciting biotechnology company, developing novel therapies for genetic diseases by inhalation. The company is currently focusing on splicing mutations in the CFTR gene for treating Cystic Fibrosis (CF) patients.
Company Details
- Employees
- 15
- Founded
- 2017
- Address
- The Hebrew University Of Jerusalem Silberman Building 78, Jerusalem,9190401,israel
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.splisense.com
- HQ
- Jerusalem
Splisense Questions
Splisense's website is http://www.splisense.com
Splisense's LinkedIn profile is https://il.linkedin.com/company/splisenseltd
Splisense has
15 employees.
View email and phone details for 15
employees at Splisense.
Splisense's industry is
Biotechnology Research
Splisense's top competitors are
Kahr-Medical Ltd.,
Nectin Therapeutics,
Eleven Therapeutics,
Curesponse,
Enlivex Therapeutics (Nasdaq: Enlv),
Neotx Therapeutics Ltd,
1e Therapeutics,
Cytora Stem,
Bionanosim,
Scinai Immunotherapeutics Ltd..
Splisense's categories are Biotechnology Research
Splisense's founding year is 2017
